Dr Andrew Mountain

 

Business Engagement Partner

Contact details

Health Services Research Centre,
Medical School
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

About

Andy Mountain became the Business Engagement Partner for MDS in May 2012. He is responsible for identifying and developing new opportunities and strategies for engagement with business, and leading on developing and coordinating strategic business partnerships.

Qualifications

  • PhD in Molecular Genetics, University of Leeds, 1978
  • BSc (Hons) in Molecular Biology, University of Edinburgh, 1974

Biography

Andy Mountain had a 10 year academic research career in molecular genetics before moving into the medical biotechnology industry in 1985. He then spent 20 years as a director of research, development and commercialisation in pioneering biotechnology companies, working for Celltech (the UK’s first biotechnology company) and Cobra (the UK’s first gene therapy company). He led many programmes for discovery and development of small molecule, protein and cell therapeutics in several therapeutic areas, especially cancer. Two of the antibody therapeutics programmes he led resulted in significant new drugs reaching the market. He also led on development of new manufacturing systems for antibody therapies in both mammalian cells and bacteria.

In 2008, Andy became Head of Commercial Development for the University, playing a key role in the establishment of Alta Innovations as the University’s technology transfer company and being its Chief Operations Officer until 2012.

He has published more than 60 peer-reviewed papers in the scientific and clinical literature, including comprehensive reviews of gene expression systems, therapeutic antibodies and gene therapy

Other activities

Andy Mountain has served as a member of many research council and other government committees assessing biotechnology grant applications.

Publications

  • Mountain.A and Adair.J (1992) Engineering antibodies for therapy. In “ Biotechnology and Genetic Engineering Reviews”, volume 10, Ed M.Tombs, Intercept Ltd, pp1-142.57.   
  • Mountain.A (2000) Gene therapy – the first decade. Trends in Biotechnology 18:119-128.
  • Hamman.P, Hinman.L, Hollander.I, Beyer.C, Lindh.D, Holcomb.R, Hallett.W, Upeslacis.J, Schochat.D, Mountain.A, Flowers.D and Bernstein.I. (2002) Gemtuzumab ozogamicin (Mylotarg), A potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chemistry 13:47-58.
  • Antoniou.M, Harland.L, Mustoe.T, Williams.S, Holdstock.J, Yague.E,  Mulcahy.T, Griffiths.M, Edwards.S, Ioannou.P, Mountain.A and Crombie.R, (2003) Transgenes encompassing dual promoter CpG islands from the human TBP and HNRPA2 loci are resistant to heterochromatin-mediated silencing.   Genomics 82:269-279.
  • Lipinski.K, Djeha.H, Gawn.J, Cliffe.S, Maitland.N, Palmer.D, Mountain.A, Irvine.A and Wrighton.C (2004) Optimisation of a β-catenin-dependent promoter for tumour-specific cancer gene therapy.   Molecular Therapy 10:150-161.
  • Palmer.D, Mautner.V, Mirza.D, Oliff.S, Gerritsen.W, van der Sijp.J, Hubscher.S, Reynolds.G, Bonney.S, Rajaratnam.R, Hull.D, Horne.M, Ellis.J, Mountain.A, Hill.S, Harris.P. Searle.P, Young.L, James.N and Kerr.D.   (2004) Virus-directed enzyme prodrug therapy: Intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. Journal of Clinical Oncology 22:1-7.
  • Hamann.P. Hinman.L, Beyer.C, Lindh.D, Upeslacis.J, Shochat.D and Mountain.A (2005) A calicheamicin conjugate with a fully humanised anti-MUC1 antibody shows potent antitumour effects in breast and ovarian tumour xenografts.   Bioconjugate Chemistry 16:3 54-360.

Back to top